Abstract:Schistosomiasis is a relatively neglected parasitic disease that afflicts more than 250 million people worldwide, for which the control strategy relies mainly on mass treatment with the only available drug, praziquantel (PZQ). This approach is not sustainable and is a priority for developing novel drug candidates for the treatment and control of schistosomiasis. In our previous study, we found that DW-3-15, a kind of PZQ derivative, could significantly downregulate the expression of the histone acetyltransferase of Schistosoma japonicum ( Sj HAT). In this study, several commercially available HAT inhibitors, A485, C646 and curcumin were screened in vitro to verify their antischistosomal activities against S . japonicum juveniles and adults. Parasitological studies and scanning electron microscopy were used to study the primary action characteristics of HAT inhibitors in vitro . Quantitative real-time PCR was employed to detect the mRNA level of Sj HAT after treatment with different HAT inhibitors. Our results demonstrated that curcumin was the most effective inhibitor against both juveniles and adults of S . japonicum , and its schistosomicidal effects were time- and dose dependent. However, A485 and C646 had limited antischistosomal activity. Scanning electron microscopy demonstrated that in comparison with DW-3-15, curcumin caused similar tegumental changes in male adult worms. Furthermore, both curcumin and DW-3-15 significantly decreased the Sj HAT mRNA level, and curcumin dose-dependently reduced the Sj HAT expression level in female, male and juvenile worms. Among the three commercially available HATs, curcumin was the most potent against schistosomes. Both curcumin and our patent compound DW-3-15 markedly downregulated the expression of Sj HAT, indicating that Sj HAT may be a potential therapeutic target for developing novel antischistosomal drug candidates. Schistosomiasis is a zoonotic parasitic disease caused by Schistosoma spp . infection. Due to the lack of effective vaccines for schistosomiasis, PZQ is the only available drug chosen for the treatment and control of schistosomiasis in most developing countries. Drug resistance due to long-term, large-scale and single-agent use has been a great concern. Therefore, there is an urgent need for new therapies. In our previous study, we developed the patented compound DW-3-15 (patent no. ZL201110142538.2), which has significant and stable antiparasitic activity, and can significantly decrease the expression of S . japonicum histone acetyltransferase ( Sj HAT). As we known, HATs are a class of epigenetic enzymes that are crucial for chromatin restructuring and transcriptional regulation in mammals and in parasitic development, and are thus promising targets for antischistosomal therapeutic development. In this study, we assessed three commercial HATs, including two selective p300/CBP inhibitors A485 and C646, and one natural compound, curcumin. Our results demonstrated that curcumin had the most potent worm-killing efficacy against S . japonicum juveniles and adults. In contrast, A485 and C646 displayed no effects on adult worms or mild effects on juveniles. Moreover, curcumin caused severe damage to the tegument of male worms, and the damage was similar to that of DW-3-15. Coincidentally, both curcumin and DW-3-15 significantly downregulated the expression of Sj HAT, indicating that Sj HAT might be an effective target for the development of novel therapeutic drugs. The screening and identification of selective HAT inhibitors may be a promising strategy for developing novel antischistosomal agents.

[Histone deacetylase and histone acetyltransferase inhibitors as antischistosomal agents: a review]

Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S . mansoni larval and adult worm stages

Schistosomicidal effects of histone acetyltransferase inhibitors against Schistosoma japonicum juveniles and adult worms in vitro

Protein Kinases: Potential Drug Targets Against Schistosoma japonicum

Small change, big difference: A promising praziquantel derivative designated P96 with broad-spectrum antischistosomal activity for chemotherapy of schistosomiasis japonica

Aldose Reductase from Schistosoma Japonicum: Crystallization and Structure-Based Inhibitor Screening for Discovering Antischistosomal Lead Compounds.

Targeting the Schistosoma mansoni nutritional mechanisms to design new antischistosomal compounds

A Review of Nanotechnology for Targeted Anti-schistosomal Therapy

Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni

A comprehensive exploration of schistosomiasis: Global impact, molecular characterization, drug discovery, artificial intelligence and future prospects

Current drug strategies for the treatment and control of schistosomiasis

Computational Insights into Natural Antischistosomal Metabolites as SmHDAC8 Inhibitors: Molecular Docking, ADMET Profiling, and Molecular Dynamics Simulation

The Existing Drug Nifuroxazide as an Antischistosomal Agent: In Vitro, In Vivo, and In Silico Studies of Macromolecular Targets

Nanotechnological approaches in the treatment of schistosomiasis: an overview

In vivo Therapeutic Effects and Mechanisms of Hydroxyasiaticoside Combined With Praziquantel in the Treatment of Schistosomiasis Induced Hepatic Fibrosis

How improvements to drug effectiveness impact mass drug administration for control and elimination of schistosomiasis

3-oxoacyl-ACP reductase from Schistosoma japonicum: integrated in silico-in vitro strategy for discovering antischistosomal lead compounds.

Antischistosomal Properties of Hederacolchiside A1 Isolated from Pulsatilla chinensis

Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022

A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1

Effect of praziquantel on the differential expression of mouse hepatic genes and parasite ATP binding cassette transporter gene family members during Schistosoma mansoni infection